Phase 2 Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a high-grade brain tumour (specifically a WHO grade 4 malignant glioma, such as glioblastoma or astrocytoma), confirmed by a recent biopsy or surgery.
- People aged 18 or older.
- People who have a reasonable level of physical functioning, as measured by a standard medical scoring tool called the Karnofsky Performance Scale (scores between 60 and 100) (confirm with trial site).
- People whose blood test results meet certain minimum standards, including platelet counts and kidney function levels (confirm with trial site for exact values).
- People who are able to give informed consent to participate.
- People who are planning to receive both radiation therapy and chemotherapy as part of their treatment.
Who may not be able to join:
- People who have had a blood clot in a deep vein, in the lungs, or in a brain vein within the past 6 months.
- People who are currently pregnant.
- People with a significant risk of bleeding, including those with a history of bleeding in the brain, active bleeding at the time of enrolment, a significant bleeding episode within the past 14 days, a stroke or traumatic brain injury within the past 6 months, or major surgery or a major medical procedure within the past 48 hours.
- People who have an allergy to a blood-thinning medication called apixaban, or for whom blood-thinning medication in general is not considered safe.
- People who are already taking certain blood-thinning medications (such as heparin, fondaparinux, dabigatran, edoxaban, or rivaroxaban) and are unable to switch to the study medication.
- People who are taking certain other medications known to interact with apixaban (strong CYP3A4 inhibitors and P-glycoprotein inhibitors) (confirm with trial site).
- People who need to take full-dose blood thinners for another medical reason, such as atrial fibrillation or a mechanical heart valve.
- People whose life expectancy is estimated to be less than 3 months.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Alissa A Thomas, MD, University of Vermont Medical Center
Phone: 802-847-8400
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Safety of apixaban as determined by bleeding risk
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.